semaglutide and arrhythmia Metabolic remodelling in atrial fibrillation: manifestations, mechanisms clinical implications GLP-1 Weight Loss & AFib
Description
Results of the phase 3b randomized clinical trial found participants using tirzepatide lost 50.3 lbs (22.8 kg) and participants on semaglutide lost 33.1 lbs (15.0 kg)
Study Design: Participants included overweight and obese patients, some with concomitant conditions such as type 2 diabetes
Understand Medicare may require you to try other medications before approving Ozempic
It directly addresses the metabolic signaling dysfunction that drives those symptoms
Regaining 20 to 30 pounds suggests the maintenance strategy needs strengthening
